PTC Therapeutics drops as it pulls Translarna NDA resubmission
Source: SeekingAlpha
2026-02-12 17:41:40 ET
More on PTC Therapeutics
- PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript
- PTC Therapeutics projects FY26 product revenue between $700M to $800M
- PTC Therapeutics downgraded at RBC as Sephience sales priced in
Read the full article on Seeking Alpha
For further details see:
PTC Therapeutics drops as it pulls Translarna NDA resubmission
PTC Therapeutics Inc.
NASDAQ: PTCT
PTCT Trading
3.85% G/L:
$69.39 Last:
135,371 Volume:
$68.41 Open:
PTCT Latest News
March 03, 2026 10:11:53 am
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
February 19, 2026 04:01:00 pm
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PTCT Stock Data
$5,800,830,036
75,872,448
1.06%
134
N/A
Biotechnology & Life Sciences
Healthcare
US
Warren
